1.75
+10.76%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Niki BioSolutions,
Its shares trade under the ticker NIKI. It has been listed since 17 July 2026. In the fiscal year to 31 December 2025, it reported a net loss of $1.4m. At that date it held total assets of $18.7m and shareholders' equity of $23.2m.
Niki BioSolutions, Inc., through its subsidiaries, operates as a clinical-stage biopharmaceutical company and engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in a Phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in a Phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa. The company also develops SACT-COV19, a repurposed small molecule, which is in a preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule, which is in a preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule, which is in a preclinical trial for the treatment of gram+ve bacterial infections. The company was formerly known as Aptorum Group Limited and changed its name to Niki BioSolutions, Inc. in July 2026. Niki BioSolutions, Inc. was incorporated in 2010 and is headquartered in Princeton, New Jersey. Niki BioSolutions, Inc. operates as a subsidiary of Jurchen Investment Corporation.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Listed since
- 17 Jul 2026
- Website
- aptorumgroup.com ↗
- Head office
- 116 VILLAGE BOULEVARD, PRINCETON, NJ, 08540
- Incorporated in
- E9
- Classification
- Measuring & Controlling Devices, NEC
- Filer status
- Non-accelerated filer<br>Smaller reporting company
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Niki BioSolutions' SACT-1 is in Phase 1 trials for neuroblastoma treatment in the US.
- SACT-COV19 is in preclinical trials for coronavirus disease treatment globally.
- ALS-4 is in Phase 1 trials for bacterial infections including MRSA in the US.
Weaknesses
- SACT-2 and SACT-3 are in early preclinical stages without specific indications.
- ALS-1 and ALS-2/3 are in preclinical trials for bacterial infections without trial phases specified.
- The company's name change from Aptorum Group Limited to Niki BioSolutions in July 2026 may cause brand confusion.
Opportunities
- Repurposed drugs like SACT-1 and ALS-4 could accelerate market entry in oncology and infectious diseases.
- SACT-COV19's preclinical stage offers potential for rapid development in pandemic response.
- US clinical trials for SACT-1 and ALS-4 provide access to a large patient population.
Threats
- SACT-1's Phase 1 trial for neuroblastoma faces competition from established oncology treatments.
- ALS-4's Phase 1 trial for bacterial infections may encounter resistance from existing antibiotics.
- SACT-COV19's preclinical stage requires significant funding for advancement to clinical trials.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.